featured
No PFS Benefit of Paclitaxel + Reparixin in Metastatic TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
Breast Cancer Res Treat 2021 Sep 03;[EPub Ahead of Print], LJ Goldstein, M Mansutti, C Levy, JC Chang, S Henry, I Fernandez-Perez, J Prausovà, E Staroslawska, G Viale, B Butler, S McCanna, PA Ruffini, MS Wicha, AF SchottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.